Complement regulatory molecules on human myelin and glial cells: Differential expression affects the deposition of activated complement proteins

Journal of Neurochemistry

Volumn 66, Issue 1, 1996, Pages 303-312

  Koski, Carol L ^a,c   Estep, Alden E ^a   Sawant Mane, Suneeti ^a   Shin, Moon L ^a   Highbarger, Lane ^a   Hansch, Gertrude M ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

C5b 9; Complement; Complement regulatory proteins; Myelin; Schwann cell

Indexed keywords

COMPLEMENT COMPONENT C3 RECEPTOR; MYELIN;

ANTIBODY TITER; ARTICLE; CAUDA EQUINA; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION; DEMYELINATION; GLIA CELL; HUMAN; HUMAN CELL; POLYMERIZATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SCHWANN CELL;

EID: 0030052638     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.66010303.x     Document Type: Article

References (58)

1. Ahearn J. M. and Fearon D. T. (1989) Structure and function of the complement receptors, CRI (CD35) and CR2 (CD21). Adv. Immunol. 46, 183-219.
2. Anderson D. J., Abbott A. F., and Jack R. M. (1993) The role of complement component C3b and its receptors in sperm-oocyte interaction. Proc. Natl. Acad. Sci. USA 90, 10051-10055.
3. Arnason B. G. W. and Soliven B. (1993) Acute inflammatory demyelinating polyradiculoneuropathy, in Peripheral Neuropathy, 3rd edit. (Dyck P. J. and Thomas P. K., eds), pp. 1437-1497. W. B. Saunders, Philadelphia.
4. Atkinson J. P., Krych M., Nickells M., Birmingham D., Subramanian V. B., Clemenza L., Alvarez J., and Liszewki K. (1994) Complement receptors and regulatory proteins: immune adherence revisited and abuse by microorganism. Clin. Exp. Immunol. 97 (Suppl. 2), 1-3.
5. Bruck W. and Friede R. L. (1991) The role of complement in myelin phagocytosis during PNS wallerian degeneration. J. Neurol. Sci. 103, 182-187.
6. Cole J. L., Housley G. A. Jr., Dykmaan T. R., MacDermott R. P., and Atkinson J. P. (1985) Identification of an additional class of C-3 binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc. Natl. Acad. Sci. USA 82, 859-863.
7. Compston D. A. S., Morgan B. P., Oleesky D., Fifield R., and Campbell A. K. (1986) Cerebrospinal fluid in demyelinating disease. Neurology 36, 1503-1506.
8. Compston D. A. S., Morgan B. P., Campbell A. K., Wilkins P., Cole G., Thomas N. D., and Jasani B. (1989) Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol. Appl. Neurobiol. 15, 307-316.
9. Davies A., Simmons D. L., Hale G., Harrison R. A., Tighe H., Lachmann P. J., and Waldmann H. (1989) CD59, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of complement membrane attack complex on homologous cells. J. Exp. Med. 170, 637-654.
10. Feasby T. E., Gilbert J. J., Hahn A. F., and Neilson M. (1987) Complement depletion suppresses Lewis rat experimental allergic neuritis. Brain 19, 97-103.
11. Kabat E. A. and Mayer M. M. (1964) Experimental Immunochemistry, pp. 149-153 Charles C. Thomas. Springfield, Illinois.
12. Korty P. E., Brando C., and Shevach E. M. (1991) CD59 functions as a signal transducting molecule for human T cell activation J. Immunol. 146, 4092-4098.
13. Koski C. L., Humphrey R., and Shin M. L. (1985a) Anti-peripheral myelin antibody in patients with demyelinating neuropathy. Quantitative and kinetic determination of serum antibody by complement fixation. Proc. Natl. Acad. Sci. USA 82, 905-909.
14. Koski C. L., Vanguri P., and Shin M. L. (1985b) Activation of the alternative pathway of complement by human peripheral nerve myelin. J. Immunol. 134, 1810-1814.
15. Koski C. L., Gratz E., Sutherland J., and Mayer R. F. (1986) Clinical correlation with antiperipheral myelin antibodies in Guillain-Barré syndrome. Ann. Neurol. 19, 573-577.
16. Koski C. L., Sanders M. E., Swoveland P. T., Shin M. L., Frank M. M., and Joiner K. A. (1987) Activation of terminal components of complement in patients with Guillain-Barre syndrome and other demyelinating neuropathies. J Clin. Invest. 80, 1492-1497.
17. Kroczek R. A., Gunter K. C., Germain R. N., and Shevach E M. (1986) Thy-1 functions as a signal transduction molecule in T lymphocytes and transfected B lymphocytes. Nature 322, 181-184.
18. Levine S., Cochrane C. G., Carpenter C. B., and Behan P. O. (1971) Allergic encephalomyelitis: effect of complement depletion with cobra venom. Proc. Soc. Exp. Biol. Med. 138, 285-289.
19. Linington C., Morgan B. P., Scolding N. J., Wilkins P., Piddlesden S., and Compston D. A. S. (1989) The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 112, 895-911.
20. McNearney T., Ballard L., Seya T., and Atkinson J. P. (1989) Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. J. Clin. Invest. 84, 538-545.
21. Medof M. E., Kinoshita T., and Nussenzzwig V. (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Exp. Med. 160, 1558-1578.
22. Meri S., Morgan B. P., Davies A., Daniels R. H., Olavesen M. G., Waldmann H., and Lachmann P J. (1990) Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71, 1-9.
23. Morariu M. A. and Dalmasso A. P. (1978) Experimental allergic encephalomyelitis in cobra venom factor-treated and C4-deficient guinea pigs. Ann. Neurol. 4, 427-430.
24. Morgan B. P., Van den Berg C. W., Davies V., Hallet M. B., and Horejsi V. (1993) Cross-linking of CD59 and of other phosphatidylinositol-anchored molecules on neutrophils triggers cell activation via tyrosine kinase. Eur. J. Immunol. 23, 2841-2850.
25. Naniche D., Varior-Kreshnan G., Cernoi F., Wild T. F., Rossi B., Radurdim-Combe C., and Gerlier D. (1993) Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67, 6025-6032.
26. Needham L. K., Tennekoon G. I., and McKhann G. M. (1987) Selective growth of rat Schwann cells in neuron- and serum-free primary culture. J. Neurosci. 7, 1-9.
27. Nicholson-Weller A., Burge J., Fearon D. T., Weller P. F., and Austen K. F. (1982) Isolation of a human erythrocyte membrane glycoprotein with decay accelerating activity for C3-convertases of the complement system J. Immunol. 129, 184-189.
28. Norton W. T. (1974) Isolation of myelin from nervous tissue. Methods Enzymol. 31 (Part A), 435-444.
29. Nose M., Katoh W., and Okada N. (1990) Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology 70, 145-149.
30. Nowicki B., Hart A., Coyne K. E., Lublin D. M., and Nowicki S. (1993) Short consensus repeat-3 domain of recombinant decay-accelerating factor is recognized by Escherichia coli recombinant DR adhesin in a model of a cell-cell interaction. J. Exp. Med. 178, 2115-2121.
31. Pabst H., Day N. K., Gewurz H., and Good R. A. (1971) Prevention of allergic encephalomyelitis with cobra venom factor. Proc. Soc. Exp. Biol. Med. 136, 555-560.
32. Piddlesden S. J. and Morgan B. P. (1993) Killing of rat glial cells by complement: deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. J. Neuroimmunol. 48, 169-175.
33. Ramm L. E. and Mayer M. M. (1980) Life-span and size of the trans-membrane channel formed by large doses of complement. J. Immunol. 124, 2281-2287.
34. Rollins S. A. and Sims P. J. (1990) The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J. Immunol. 144, 3478-3483.
35. Rosse W. F. (1989) Paroxysmal nocturnal hemoglobinuria: the biochemical defects and the clinical syndrome. Blood Rev. 3, 192-200.
36. Rutkowski J. L., Tennekoon G. I., and McGillicuddy J. E. (1992) Selective culture of mitotically active human Schwann cells from adult sural nerves. Ann. Neurol. 31, 580-586.
37. Sanders M. E., Koski C. L., Robbins D., Shin M. L., Frank M. M., and Joiner K. A. (1986) Activated terminal complements in cerebra-spinal fluid in Guillain-Barre syndrome and multiple sclerosis. J. Immunol. 136, 4456-4459.
38. Sawant-Mane S., Clark M. B , and Koski C. L. (1991) In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes. Ann. Neurol 29, 397-404.
39. Sawant-Mane S., Estep A., and Koski C. L. (1994a) Antibody of patients with Guillain-Barre syndrome mediates complement dependent cytolysis of rat Schwann cells: susceptibility to cytolysis reflects Schwann cell phenotype. J. Neuroimmunol. 49, 145-152.
40. Sawant-Mane S., Piddlesden S. J., Morgan B. P., and Koski C. L. (1994b) Rat inhibitory protein (RIP) regulates complement dependent cytolysis of rodent Schwann cells (Sch.C). (Abstr.) FASEB J. 8, A767.
41. Schonermark S , Rauterberg E. W., Shin M. L., Lore S., Roelcke D., and Hänsch G. M. (1986) Homologous species restriction in lysis of human erythrocytes: a membrane derived protein with C8-binding capacity functions as an inhibitor. J. Immunol. 136, 1772-1776.
42. Scolding N. J., Morgan B. P., Houston A., Campbell A., Linington C., and Compston D. A. S. (1989) Normal rat serum cytotoxicity against syngeneic oligodendrocytes: complement activation and attack in the absence of anti-myelin antibodies. J. Neurol. Sci. 89, 289-300.
43. Shin M. L. and Koski C. L. (1992) The complement system in demyelination, in Myelin: Biology and Chemistry. (Martenson R. E., ed), pp. 801-831. CRC Press, Boca Raton, Florida.
44. Shirazi Y., Imagawa D. K., and Shin M. L. (1987) Release of leukotriene B4 from sublethally injured oligodendrocytes by terminal complement complexes. J. Neurochem. 48, 271-278.
45. Shirazi Y., McMorris F. A., and Shin M. L. (1989) Arachidonic acid mobilization and phosphoinositide turnover by the terminal complement complex, C5b-9, in rat oligodendrocytes X C6 glioma cell hybrids. J. Immunol. 142, 4385-4391.
46. Shirazi Y., Rus H. G., MacKlin W. B., and Shin M. L. (1993) Enhanced degradation of messenger RNA encoding myelin proteins by terminal complement complexes in oligodendrocytes. J. Immunol. 150, 4581-4590.
47. Sugita Y., Nakano Y., and Tomita M. I. (1988) Isolation from human erythrocytes which inhibits the formation of complement transmembrane channels. J. Biochem. (Tokyo) 104, 633-637.
48. Thom D., Powell A. G., Lloyd C. W., and Rees D. A. (1977) Rapid isolation of plasma membrane in high yield from cultured fibroblasts. Biochem. J. 168, 187-194.
49. 0 protein in Golgi complex membranes and myelin of developing rat Schwann cells. J. Cell Biol. 90, 1-6.
50. Trapp B. D., Andrews S. B., Wong A., O'Connell M., and Griffen J. W. (1989) Co-localization of the myelin-associated glycoprotein and the microfilament components, F-actin and spectrin, in Schwann cells of myelinated nerve fibres. J. Neurocytol. 18, 47-60.
51. Vanguri P. and Shin M. L. (1986) Activation of complement by myelin: identification of Cl-binding proteins of human myelin from central nervous tissue. J. Neurochem. 46, 1535-1541.
52. Vanguri P., Koski C. L., Silverman B., and Shin M. L. (1982) Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin specific antibodies. Proc. Natl. Acad. Sci. USA 79, 3290-3294.
53. Vedeler C. A. and Matre R. (1990) Peripheral nerve CR1 express in situ cofactor activity for degradation of C3b. J. Neuroimmunol. 26, 51-56.
54. Vriensendorp F. J., Flynn R. E., Papolla M. A., and Koski C. L. (1995) Complement depletion affects demyelination and inflammation in experimental allergic neuritis. J. Neuroimmunol. 58, 157-165.
55. Weichselbaum R. R., Dahlberg W., and Little J. B. (1985) Inherently radioresistant cells exist in some human tumors. Proc Natl. Acad. Sci. USA 82, 4732-4735.
56. Wren D. R. and Noble M. (1989) Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in the absence of antibody. Proc. Natl. Acad. Sci. USA 86, 9025-9029.
57. Yang C., Jones J. L., and Barnum S. R. (1993) Expression of decay-accelerating factor (CD55) and membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes. J. Neuroimmunol. 47, 123-132.
58. Zajicek J., Wing M. G., Lachmann P. J., and Compston D. A. (1992) Mechanisms of oligodendrocyte interaction with normal human serum - defining the role of complement. J. Neurol. Sci. 108, 65-72.